OVCAS1
MCID: OVR114
MIFTS: 39

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 56 29
Ovarian Cancer, Susceptibility to, 1 56 13
Ovarian Cancer, Susceptibility to 56
Malignant Neoplasm of Ovary 71
Epithelial Ovarian Cancer 71
Ovarian Carcinoma 71
Ovarian Cancer 56
Ovcas1 56

Classifications:



External Ids:

OMIM 56 607893
UMLS 71 C0029925 C0677886 C1140680

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian cancer, susceptibility to, 1, is related to breast-ovarian cancer, familial 2 and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To). The drugs Diclofenac and Fosaprepitant have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lung.

More information from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 910)
# Related Disease Score Top Affiliating Genes
1 breast-ovarian cancer, familial 2 12.7
2 hereditary breast ovarian cancer syndrome 12.7
3 breast-ovarian cancer, familial 3 12.6
4 breast-ovarian cancer, familial 4 12.6
5 familial ovarian cancer 12.3
6 hereditary site-specific ovarian cancer syndrome 12.2
7 ovarian epithelial cancer 12.1
8 fallopian tube carcinoma 11.7
9 pancreatic cancer 11.6
10 paraneoplastic cerebellar degeneration 11.6
11 ovarian germ cell cancer 11.6
12 ovarian small cell carcinoma 11.6
13 breast cancer 11.5
14 lynch syndrome 11.5
15 ovarian disease 11.5
16 ovarian melanoma 11.4
17 malignant ovarian cyst 11.4
18 ovarian lymphoma 11.4
19 breast-ovarian cancer, familial 1 11.3
20 atypical teratoid rhabdoid tumor 11.1
21 ovarian malignant mesothelioma 11.1
22 ovary sarcoma 11.1
23 ovary epithelial cancer 11.1
24 ovary neuroendocrine neoplasm 11.1
25 ovarian clear cell malignant adenofibroma 11.1
26 granulosa cell tumor of the ovary 11.1
27 gynandroblastoma 11.1
28 neutropenia 11.0
29 endometriosis 10.9
30 serous cystadenocarcinoma 10.9
31 endometrial cancer 10.8
32 ovary adenocarcinoma 10.8
33 adenocarcinoma 10.8
34 cystadenocarcinoma 10.8
35 alopecia 10.7
36 ovarian cyst 10.7
37 neuropathy 10.7
38 peripheral nervous system disease 10.7
39 thrombocytopenia 10.7
40 malignant epithelial tumor of ovary 10.7
41 infertility 10.6
42 severe combined immunodeficiency 10.6
43 mucositis 10.6
44 peritonitis 10.6
45 primary peritoneal carcinoma 10.6
46 ovarian serous carcinoma 10.6
47 b-cell lymphoma 10.6
48 cystadenoma 10.6
49 47,xyy 10.6
50 colorectal cancer 10.5

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 562)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Fosaprepitant Approved Phase 4 172673-20-0 219090
3
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
7
Ferrous fumarate Approved Phase 4 141-01-5
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9
Remifentanil Approved Phase 4 132875-61-7 60815
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
16
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
17
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
18 Neurotransmitter Agents Phase 4
19 Progestins Phase 4
20 Neurokinin-1 Receptor Antagonists Phase 4
21 neurokinin A Phase 4
22
Substance P Phase 4 33507-63-0 44359816
23 Follicle Stimulating Hormone Phase 4
24
Apatinib Phase 4 811803-05-1
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Platelet Aggregation Inhibitors Phase 4
28 Anesthetics Phase 4
29 Central Nervous System Depressants Phase 4
30 Anesthetics, Local Phase 4
31 Hypnotics and Sedatives Phase 4
32 Anesthetics, General Phase 4
33 Anesthetics, Inhalation Phase 4
34 Anesthetics, Intravenous Phase 4
35
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
36
Hydralazine Approved Phase 3 86-54-4 3637
37
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
38
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
39
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
40
Epirubicin Approved Phase 3 56420-45-2 41867
41
Ethanol Approved Phase 3 64-17-5 702
42
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
43
Tranexamic Acid Approved Phase 3 1197-18-8 5526
44
Atorvastatin Approved Phase 3 134523-00-5 60823
45
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
46
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
47
Ibuprofen Approved Phase 3 15687-27-1 3672
48
Mebendazole Approved, Vet_approved Phase 3 31431-39-7 4030
49
Piperazine Approved, Vet_approved Phase 3 110-85-0 4837
50
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203

Interventional clinical trials:

(show top 50) (show all 2092)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
4 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
5 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
6 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
7 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
8 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
9 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
10 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
11 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
12 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
13 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
14 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
15 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
16 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
17 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
18 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
20 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
21 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
22 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
23 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
24 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
26 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
27 The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
28 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
29 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
30 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
31 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
32 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
33 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
34 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
35 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
36 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
37 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
38 Phase 3 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
39 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
40 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
41 Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
42 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
43 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
44 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine
45 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
46 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00102375 Phase 3 Topotecan
47 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
48 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
49 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
50 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

40
Breast, Testes, Lung, T Cells, Ovary, Prostate, Colon

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 85)
# Title Authors PMID Year
1
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. 56
11440995 2001
2
Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. 61
31277885 2019
3
Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer. 61
31610315 2019
4
Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases. 61
31301021 2019
5
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer. 61
30541753 2019
6
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. 61
30229512 2019
7
The relation of healthy and Western dietary patterns to the risk of endometrial and ovarian cancers: a systematic review and meta-analysis. 61
30806608 2019
8
Chromatin-Remodeling Factor SPOC1 Acts as a Cellular Restriction Factor against Human Cytomegalovirus by Repressing the Major Immediate Early Promoter. 61
29743358 2018
9
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 61
29454514 2018
10
Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. 61
28536993 2017
11
Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer. 61
28560285 2017
12
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. 61
26194361 2016
13
[Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer]. 61
27116987 2016
14
Expression and clinical significance of cortactin protein in ovarian neoplasms. 61
26243395 2016
15
Egg intake and cancers of the breast, ovary and prostate: a dose-response meta-analysis of prospective observational studies. 61
26293984 2015
16
Unexpected ovarian malignancy following laparoscopic excision of adnexal masses. 61
24964925 2014
17
Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. 61
24680770 2014
18
Contrast harmonic endoscopic ultrasonography in the characterization of pancreatic metastases (with video). 61
24713844 2014
19
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. 61
23756764 2014
20
High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. 61
24361578 2014
21
Management and prevention of chylous leakage after laparoscopic lymphadenectomy. 61
25268098 2014
22
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 61
23921967 2013
23
A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. 61
23557323 2013
24
SPOC1 modulates DNA repair by regulating key determinants of chromatin compaction and DNA damage response. 61
23034801 2012
25
Fibroblast growth factor receptor 3 is highly expressed in rarely dividing human type A spermatogonia. 61
22777346 2012
26
Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures. 61
22561039 2012
27
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer. 61
21380784 2012
28
[III. Ovarian cancer 1. Ovarian clear cell carcinoma]. 61
22545287 2012
29
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. 61
22001143 2012
30
Current clinical practice in cytoreductive surgery for advanced ovarian cancer: a European survey. 61
21892096 2011
31
Laparoscopic major gynecologic surgery in patients with prior laparotomy bowel resection. 61
22643497 2011
32
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting. 61
21072604 2010
33
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. 61
19552944 2009
34
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. 61
19018599 2009
35
Psychosocial consequences of genetic counseling: a population-based follow-up study. 61
19120380 2009
36
[Relationship between hormone therapy in women with ovarian malignancy and prognosis]. 61
19087569 2008
37
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. 61
18794120 2008
38
[Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice]. 61
19080673 2008
39
Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. 61
17688927 2007
40
Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. 61
17581421 2007
41
Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. 61
17354232 2007
42
Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. 61
17359531 2007
43
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. 61
17043634 2006
44
[Influence of gonadotropin-releasing hormone agonist on the effects of chemotherapy upon ovarian cancer: an experimental study with rat model]. 61
16029659 2005
45
Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. 61
15935955 2005
46
Gene expression in the spermatogenically inactive "dark" and maturing "light" testicular tissues of the prepubertal colt. 61
15223842 2004
47
Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. 61
15067357 2004
48
[Role of positron emission tomography in diagnosis of recurrent ovarian cancer]. 61
14728852 2003
49
[An experimental research in the inhibiting effect of bFGF-MAb on the growth of ovarian cancer cells and transplanted tumor]. 61
14619564 2003
50
Reduction of blood loss during extensive pelvic procedures by aortic clamping--a preliminary report. 61
12504633 2003

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

GO Terms for Ovarian Cancer 1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....